LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Listă Acțiuni・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Închisă

SectorSănătate

235.49 1.33

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

229.94

Maxim

240.55

Indicatori cheie
By Trading Economics
Venit	-58M -13M
Vânzări	-7.9M 52M
P/E Medie Sector	29.958 49.888
EPS	-0.67
Marjă de profit	-25.801
Angajați	47
EBITDA	-49M 17M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+15.53% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.8B 4.6B
Deschiderea anterioară	234.16
Închiderea anterioară	235.49

Sentimentul știrilor

By Acuity

50%

155 / 344 Clasament în Healthcare

Ligand Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 iun. 2026, 21:51 UTC

Principalele dinamici ale pieței

Merlin Shares Rally After Defense Department's Design Review Wraps

4 iun. 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 iun. 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 iun. 2026, 23:42 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 iun. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia to Enter Trading Halt

4 iun. 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 iun. 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 iun. 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 20:44 UTC

Achiziții, Fuziuni, Preluări

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 iun. 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 iun. 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 iun. 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 iun. 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 iun. 2026, 18:47 UTC

Achiziții, Fuziuni, Preluări

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 iun. 2026, 18:38 UTC

Câștiguri

Money Quote: Tech Weakness in Context -- WSJ

4 iun. 2026, 18:24 UTC

Câștiguri

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 iun. 2026, 16:58 UTC

Câștiguri

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 iun. 2026, 16:38 UTC

Câștiguri

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 iun. 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 iun. 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 iun. 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparație

Modificare preț

Ligand Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

15.53% sus

Prognoză pe 12 luni

Medie 270.8 USD 15.53%

Maxim 289 USD

Minim 255 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLigand Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Ligand Pharmaceuticals Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

155 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.